Incorporating Immunotherapies into the Evolving Standard of Care for Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia
{{output}}
Survival for pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) exceeds 90% in high-income countries due to risk-adapted chemotherapy and measurable residual disease (MRD)-guided strategies. However, relapse remains a leading cause of death, and... ...
